Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Positive Phase III Data For Tasocitinib Give Pfizer A Badly Needed Pipeline Lift

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Pfizer retains its lead in race to bring a novel oral RA drug to market

You may also be interested in...



Avanir Relying On PBA Drug Nuedexta For Success

Approved last year for pseudobulbar affect and gradually gaining sales and formulary adoption, Nuedexta will be studied in additional CNS indications.

Avanir Relying On PBA Drug Nuedexta For Success

Approved last year for pseudobulbar affect and gradually gaining sales and formulary adoption, Nuedexta will be studied in additional CNS indications.

Glimpse Of New Phase III Data Hints Pfizer's Eagerly-Awaited Oral RA Drug Is Still On Track

JAK inhibitor tofacitinib, formerly called tasocitinib, meets primary endpoints in second Phase III study, could be filed in second half of 2011.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS071538

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By